Search results (1320)
« Back to PublicationsEconomic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: Results from a retrospective, longitudinal survey (MELODY study)
Johnston K. et al, (2012), European Journal of Cancer, 48, 2175 - 2182
Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer.
Gillies RS. et al, (2012), Eur Radiol, 22, 2035 - 2043
Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer
Gillies RS. et al, (2012), European Radiology, 22, 2035 - 2043
Oxaliplatin as a radiosensitiser for upper and lower gastrointestinal tract malignancies: what have we learned from a decade of translational research?
Hill EJ. et al, (2012), Crit Rev Oncol Hematol, 83, 353 - 387
Oxaliplatin as a radiosensitiser for upper and lower gastrointestinal tract malignancies: What have we learned from a decade of translational research?
Hill EJ. et al, (2012), Critical Reviews in Oncology/Hematology, 83, 353 - 387
Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.
Leijen S. et al, (2012), Clin Cancer Res, 18, 4794 - 4805
EMERGENCE OF AN IMMUNE-RESTRICTED PROGENITOR PRIOR TO DEFINITIVE HEMATOPOIETIC STEM CELLS
Boiers C. et al, (2012), EXPERIMENTAL HEMATOLOGY, 40, S58 - S58
Guideline for the diagnosis and management of myelofibrosis
Reilly JT. et al, (2012), British Journal of Haematology, 158, 453 - 471
PERTURBATION OF FETAL LIVER HAEMATOPOIETIC STEM AND PROGENITOR CELL DEVELOPMENT BY TRISOMY 21
Roy A. et al, (2012), HAEMATOLOGICA, 97, 40 - 41
Improved survival with MEK inhibition in BRAF-mutated melanoma.
Flaherty KT. et al, (2012), N Engl J Med, 367, 107 - 114
Ipilimumab: A novel immunomodulating therapy causing autoimmune hypophysitis: A case report and review
Juszczak A. et al, (2012), European Journal of Endocrinology, 167, 1 - 5
Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review.
Juszczak A. et al, (2012), Eur J Endocrinol, 167, 1 - 5
CLINICAL DIAGNOSTIC IMPLEMENTATION OF AN INNOVATIVE CANCER CARE MODEL BASED ON COMPREHENSIVE MOLECULAR PROFILING OF TUMOUR-NORMAL PAIRS
Kaur K. et al, (2012), ANNALS OF ONCOLOGY, 23, 12 - 13
Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial.
Cummings J. et al, (2012), Br J Cancer, 106, 1766 - 1771
Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial
Cummings J. et al, (2012), British Journal of Cancer, 106, 1766 - 1771
Phase I study to determine the bioavailability and tolerability of a tablet formulation of the PARP inhibitor olaparib in patients with advanced solid tumors: Dose-escalation phase.
Gupta A. et al, (2012), JOURNAL OF CLINICAL ONCOLOGY, 30
Use of DNA repair proteins translated from biomarker screening to predict overall survival in patients with esophageal cancer treated with oxaliplatin chemotherapy
Sharma RA. et al, (2012), JOURNAL OF CLINICAL ONCOLOGY, 30
Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012
Mclornan DP. et al, (2012), British Journal of Haematology, 157, 413 - 425
In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation.
Psaila B. et al, (2012), Blood, 119, 4066 - 4072